Abeona Therapeutics Inc. Receives Stockholder Approval for Equity Incentive Plan Amendment

Abeona Therapeutics Inc. announced that stockholders have approved the Second Amended and Restated Abeona Therapeutics Inc. 2023 Equity Incentive Plan (Second A&R Plan). The approval was granted during the Company’s special meeting of stockholders held on December 20, 2024. The Board of Directors, based on the recommendation of the Compensation Committee, initially approved the Second A&R Plan on November 1, 2024, contingent on stockholder consent.

The Second A&R Plan sees an increase in the issuance of common shares, changing the number from 3,200,000 shares to 8,400,000 shares. It’s important to note that the details provided above do not encompass the entire plan. Interested parties can find the complete text of the Second A&R Plan attached as Appendix A to the Company’s definitive proxy statement on Schedule 14A, filed with the U.S. Securities and Exchange Commission on November 12, 2024, and referenced as Exhibit 10.1.

During the virtual gathering on December 20, 2024, with a quorum represented by 24,567,979 shares out of 43,593,484 outstanding and eligible to vote, the stockholders voted on and approved Proposal 1 pertaining to the increase in shares under the Second A&R Plan. The results showed 20,996,641 votes for, 2,876,261 against, and 695,077 abstentions, with no broker non-votes recorded.

Another proposal related to the possible adjournment of the Special Meeting, Proposal 2, was not presented to the stockholders as there was already a quorum established with the preliminary results showing the approval of Proposal 1.

With the endorsed changes in place, the Company has disclosed the Second Amended and Restated Abeona Therapeutics Inc. 2023 Equity Incentive Plan as Exhibit 10.1, along with the Cover Page Interactive Data File (embedded within the Inline XBRL document) as Exhibit 104.

The form was signed on behalf of Abeona Therapeutics Inc. by Joseph Vazzano, the Chief Financial Officer, on December 20, 2024.

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Abeona Therapeutics’s 8K filing here.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.